Xeris Biopharma Holdings, Inc. XERS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenue, net by Product | ||||||
| Gvoke | $20.8M-15.6% | $24.65M-2.0% | $25.15M+7.2% | $23.47M+12.6% | $20.85M-10.4% | |
| Keveyis | $11.89M-7.1% | $12.8M+7.2% | $11.94M+3.9% | $11.49M+0.5% | $11.43M+2.7% | |
| Recorlev | $49.77M+9.8% | $45.33M+22.6% | $36.98M+17.6% | $31.44M+23.2% | $25.53M+12.9% | |
| Royalty, contract and other revenue | $673K-71.7% | $2.38M+650% | $317K-91.7% | $3.83M+65.3% | $2.32M-25.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Xeris Biopharma Holdings, Inc. break its business down?
- Xeris Biopharma Holdings, Inc. (XERS) reports product revenue, net by product across 4 parts — Gvoke, Keveyis, Recorlev and Royalty, contract and other revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Xeris Biopharma Holdings, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Xeris Biopharma Holdings, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
